GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
F

Formosa Pharmaceuticals 6838.TW · TWD

Health Care · Taiwan Stock Exchange · 🇹🇼 Taiwan

Compare

21.20

+0.95%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

TWD 9.5m

FY2018FY2025

Net income

−TWD 83.6m

FY2018FY2025

Free cash flow

−TWD 137.5m

FY2018FY2025

Shareholders' equity

TWD 1.46bn

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
RevenueTWD 9.5mTWD 143.4mTWD 31.2mTWD 1.3mTWD 28.5m—TWD 1.1m—
Gross profit−TWD 1.6mTWD 119.0mTWD 27.3mTWD 333,000TWD 28.3m—TWD 300,000—
Research and developmentTWD 121.4mTWD 226.0mTWD 270.2mTWD 356.5mTWD 387.6mTWD 216.3mTWD 190.7mTWD 178.1m
Operating income−TWD 170.6m−TWD 167.8m−TWD 283.0m−TWD 406.1m−TWD 396.3m−TWD 233.6m−TWD 198.7m−TWD 189.9m
Net income−TWD 83.6m−TWD 201.0m−TWD 322.0m−TWD 406.3m−TWD 400.9m−TWD 219.7m−TWD 197.4m−TWD 172.0m
Diluted earnings per share-0.55-1.33-2.40-3.47-3.91-2.13-1.91-1.67

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assetsTWD 2.07bnTWD 2.11bnTWD 1.73bnTWD 877.9mTWD 688.7mTWD 461.8mTWD 529.2mTWD 823.6m
Cash and short-term investments—————TWD 41.9mTWD 83.4mTWD 345.1m
Total liabilitiesTWD 614.1mTWD 563.7mTWD 586.2mTWD 410.5mTWD 295.5mTWD 262.5mTWD 279.7mTWD 369.7m
Debt—TWD 25.8mTWD 29.8mTWD 6.9mTWD 3.2mTWD 6.2mTWD 6.2m—
Shareholders' equityTWD 1.46bnTWD 1.55bnTWD 1.14bnTWD 466.8mTWD 392.7mTWD 199.4mTWD 249.5mTWD 453.8m
Shares outstanding151m151m134m117m103m103m103m103m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−TWD 95.6m−TWD 128.7m−TWD 196.0m−TWD 346.1m−TWD 331.1m−TWD 175.7m−TWD 180.0m−TWD 147.7m
Capital spending−TWD 41.9m−TWD 8.2m−TWD 2.3m—−TWD 15.1m−TWD 4.7m−TWD 238,000−TWD 37.4m
Free cash flow−TWD 137.5m−TWD 136.9m−TWD 198.3m−TWD 346.1m−TWD 346.2m−TWD 180.4m−TWD 180.2m−TWD 185.1m

Latest quarters

By quarter end

Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024
RevenueTWD 3.2mTWD 911,000TWD 4.8mTWD 594,000TWD 5.9mTWD 4.3mTWD 5.3mTWD 127.8m
Gross profitTWD 508,000−TWD 5.2mTWD 3.8m−TWD 666,000TWD 2.7mTWD 638,000TWD 3.9mTWD 111.8m
Operating income−TWD 39.4m−TWD 44.6m−TWD 51.7m−TWD 34.9m−TWD 28.3m−TWD 51.9m−TWD 101.0mTWD 13.0m
Net income−TWD 48.0m−TWD 59.2mTWD 64.3m−TWD 40.7m−TWD 38.6m−TWD 46.0m−TWD 97.0m−TWD 19.0m
Diluted earnings per share-0.32-0.390.43-0.27-0.26-0.30-0.72-0.15
Cash from operations−TWD 75.0m−TWD 26.0mTWD 84.0m−TWD 76.0m−TWD 26.0mTWD 5.0m——
Capital spending——−TWD 31.0m−TWD 9.0m−TWD 1.0m−TWD 1.0m——
Free cash flow——TWD 53.0m−TWD 85.0m−TWD 27.0mTWD 4.0m——
Total assetsTWD 2.07bnTWD 2.11bnTWD 2.15bnTWD 2.06bnTWD 2.11bnTWD 2.15bnTWD 1.52bnTWD 1.74bn
Cash and short-term investments——————TWD 1.03bnTWD 1.18bn
Debt——————TWD 23.0mTWD 23.0m
Shareholders' equityTWD 1.46bnTWD 1.51bnTWD 1.57bnTWD 1.51bnTWD 1.55bnTWD 1.60bnTWD 1.01bnTWD 1.10bn

Financial ratios

Data as of 19 Oct 2026

FY2025FY2024FY2023FY2022FY2021
Gross margin-16.8%83.0%87.7%25.3%99.1%
Operating margin-879.6%-124.9%-948.8%-30844.2%-1332.0%
Net margin-880.1%-140.2%-1032.8%-30895.2%-1405.2%
Return on equity-5.7%-13.0%-28.2%-87.0%-102.1%
Return on assets-4.0%-9.5%-18.6%-46.3%-58.2%
Free cash flow yield-1.4%-3.2%———
Revenue growth-93.4%359.9%2270.5%-95.4%—
Earnings growth-58.4%-37.6%-20.8%1.3%—
Current ratio9.11x8.73x4.99x6.56x12.15x
Equity ratio70.3%73.3%66.0%53.2%57.0%
Interest coverage-172.20x-314.60x-68.65x-408.87x-172.18x
R&D as a share of sales1278.3%157.6%866.7%27108.2%1358.7%
Buybacks as a share of market value0.0%————

Growth per year

Compound annual rate

3 years5 years10 years
Revenue93.3%——
Operating income-25.1%-6.1%—
Net income-41.0%-17.6%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin76.8%78.3%——
Operating margin-221.4%-554.4%——
Net margin-186.2%-546.5%——

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-47.7-28.1-20.8-14.7-8.6
Price to sales419.839.4215.2—120.6

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.